covid
Buscar en
Endocrinología y Nutrición
Toda la web
Inicio Endocrinología y Nutrición Prevalencia, definición y manifestaciones clínicas del síndrome del ovario po...
Información de la revista
Vol. 53. Núm. S1.
Resistencia a la insulina y síndrome del ovario poliquístico (SOP)
Páginas 15-33 (septiembre 2006)
Compartir
Compartir
Descargar PDF
English PDF
Más opciones de artículo
Vol. 53. Núm. S1.
Resistencia a la insulina y síndrome del ovario poliquístico (SOP)
Páginas 15-33 (septiembre 2006)
Resistencia a la insulina y síndrome del ovario poliquístico (SOP)
Acceso a texto completo
Prevalencia, definición y manifestaciones clínicas del síndrome del ovario poliquístico
Prevalence, definition and clinical manifestations of polycystic ovary syndrome
Visitas
8387
E. Diamanti-Kandarakis
, C. Christakou
First Department of Medicine. Endocrinology Section. Laiko Hospital. Medical School of University of Athens. Atenas. Grecia
Este artículo ha recibido
Información del artículo
Resumen
Bibliografía
Descargar PDF
Estadísticas

El síndrome del ovario poliquístico (SOP) es el trastorno endocrino más prevalente de las mujeres premenopáusicas. Las intensas investigaciones realizadas han contribuido a la expansión de los conocimientos científicos sobre esta misteriosa entidad clínica y han aclarado nuevos aspectos acerca de su complejidad, que han planteado nuevos dilemas a los expertos. En el contexto de una literatura médica que se expande sin cesar, es importante considerar cuidadosamente los datos que ésta aporta, con el fin de elaborar gradualmente un enfoque clínico objetivo hacia el síndrome. Uno de los principales temas sin resolver es su definición, que sigue siendo una diana móvil, a pesar de las 2 grandes reuniones internacionales sobre el SOP que se han celebrado en la última década. En este capítulo se realiza un esfuerzo para ofrecer una actualización de los temas polémicos sobre la prevalencia y la definición del SOP, así como una vision global del cuadro clínico de este síndrome polimorfo.

Palabras clave:
SOP
Prevalencia
Definición
Enfoque clínico

PCOS is the most prevalent endocrine disorder of premenopausal women.The intensified research has contributed to the expansion of scientific knowledge regarding this mysterious clinical entity and elucidated new aspects of its complexity posing new dilemmas to experts. In the context of constantly expanding literature, it is important to consider carefully the data that are provided by the medical literature in the field, in order to gradually create an evidence-based clinical approach to the syndrome. One of the main unsolved issues is the definition of the syndrome, which remains a moving target despite two major international conferences held on PCOS, during the last decade. In this chapter an effort is made to give an update of the controversial issues of the syndrome regarding the prevalence and the definition and also to overview the clinical picture of this multifaceted syndrome.

Key words:
PCOS
Prevalence
Definition
Clinical approach
El Texto completo está disponible en PDF
Bibliografía
[1.]
The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group.
Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome.
Fertil Steril, 81 (2004), pp. 19-25
[2.]
E. Carmina, R.A. Lobo.
Polycystic ovaries in hirsute women with normal menses.
Am J Med, 111 (2001), pp. 602-606
[3.]
E. Knochenhauer, T. Key, M. Kahsar-Miller, W. Waggoner, L. Boots, R. Azziz.
Prevalence of the polycystic ovary syndrome in unselected black and white women of the Southeastern United States: a prospective study.
J Clin Endocrinol Metab, 83 (1998), pp. 3078-3082
[4.]
E. Diamanti-Kandarakis, C.R. Koulie, A.T. Bergiele, F.A. Filandra, T.C. Tsianateli, G.G. Spina, et al.
A survey of the polycystic ovary syndrome in the Greek island of Lesbos: a hormonal and metabolic profile.
J Clin Endocrinol Metab, 84 (1999), pp. 4006-4011
[5.]
M. Asunción, R.M. Calvo, J.L. San Millán, J. Sancho, S. Ávila, H.F. Escobar-Morreale.
A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain.
J Clin Endocrinol Metab, 85 (2000), pp. 2434-2438
[6.]
K.F. Michelmore, A.H. Balen, D.B. Dunger, M.P. Vessey.
Polycystic ovaries and associated clinical and biochemical features in young women.
Clin Endocrinol (Oxf), 51 (1999), pp. 779-786
[7.]
J. Adams, D.W. Polson, S. Franks.
Prevalence of polycystic ovaries in women with anovulation and idiopathic hirsutism.
BMJ, 293 (1986), pp. 355-359
[8.]
R. Azziz, K. Woods, R. Reyna, T. Key.
The prevalence and features of the polycystic ovary syndrome in an unselected population.
JCEM, 89 (2004), pp. 2745-2749
[9.]
J. Lo, S. Feigenbaum, J. Yang, A.l. Pressman, J. Selby, A.L. Go.
Epidemiology and adverse cardiovascular risk profile of diagnosed polycystic ovary syndrome.
J Clin Endocrinol Metab, 91 (2006), pp. 1357-1363
[10.]
M. Goodarzi, M. Quiñones, R. Azziz, J. Rotter, W. Hsueh, H. Yang.
PCOS in Mexican-Americans: prevalence and association with the severity of insulin resistance.
Fertil Steril, 84 (2005), pp. 766-769
[11.]
R.P. Kauffman, V.M. Baker, P. Dimarino, T. Gimpel, V.D. Castracane.
Polycystic ovarian syndrome and insulin resistance in white and Mexican American women: a comparison of two distinct populations.
Am J Obstet Gynecol, 187 (2002), pp. 1362-1369
[12.]
A.C. King, R.B. Harris, W.L. Haskell.
Effect of recruitment strategy on types of subjects entered into a primary prevention clinical trial.
Ann Epidemiol, 4 (1994), pp. 312-320
[13.]
R. Azziz, L. Sánchez, E. Knochenhauer, C. Moran, J. Lazenby, K. Stephens, et al.
Androgen excess in women: experience with over 1000 consecutive patients.
J Clin Endocrinol Met, 89 (2004), pp. 453-462
[14.]
E. Carmina, F. Rosato, A. Jann, M. Rizzo, R. Longo.
Relative prevalence of different androgen excess disorders in 950 women referred because of clinical hyperandrogenism.
J Clin Endocrinol Metab, 91 (2006), pp. 2-6
[15.]
E. Margolin, T. Zhornitzki, G. Kopernik, S. Kogan, A. Schattner, H. Knobler.
Polycystic ovary syndrome in post-menopausal women-Marker of the metabolic syndrome.
[16.]
R. Azziz.
Diagnosis of polycystic ovarian syndrome: the Rotterdam criteria are premature.
J Clin Endocrinol Metabol, 91 (2006), pp. 781-785
[17.]
S. Franks.
Diagnosis of polycystic ovarian syndrome: in defense of the Rotterdam criteria.
J Clin Endocrinol Metab, 91 (2006), pp. 786-789
[18.]
R.S. Legro, D. Driscoll, J.F. Strauss III, J. Fox, A. Dunaif.
Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome.
Proc Natl Acad Sci USA, 95 (1998), pp. 14956-14960
[19.]
S. Franks, N. Gharani, D. Waterworth, S. Batty, D. White, R. Williamson, et al.
The genetic basis of polycystic ovary syndrome.
Hum Reprod, 12 (1997), pp. 2641-2648
[20.]
A. Govind, M.S. Obhrai, R.N. Clayton.
Polycystic ovaries are inherited as an autosomal dominant trait: analysis of 29 polycystic ovary syndrome and 10 control families.
J Clin Endocrinol Metab, 84 (1999), pp. 38-43
[21.]
E. Carmina.
Diagnosis of polycystic ovary syndrome: from NIH criteria to ESHRE-ASRM guidelines.
Minerva Gynecol, 56 (2004), pp. 1-6
[22.]
M.C. Allemand, I.S. Tummon, J.L. Phy, S.C. Foong, D.A. Dumesic, D.R. Session.
Diagnosis of polycystic ovaries by three-dimensional transvaginal ultrasound.
Fertil Steril, 85 (2006), pp. 214-219
[23.]
R. Legro.
PCOS: current and future treatment paradigms.
Am J Obstet Gynecol, 179 (1998), pp. S101-S108
[24.]
P.M. Lam, R.C.W. Ma, L.P. Cheung, C.C. Chow, J.C.N. Chan, C.J. Haines.
Polycystic ovarian syndrome in Hong Kong Chinese women: patient characteristics and diagnostic criteria.
Hong Kong Med J, 11 (2005), pp. 336-341
[25.]
K. Unluhizarci, C. Gokce, H. Atmaca, F. Bayram, F. Kelestimur.
A detailed investigation of hirsutism in a Turkish population: idiopathic hyperandrogenemia as a perplexing issue.
Exp Clin Endocrinol Diabetes, 112 (2004), pp. 504-509
[26.]
C. Wijeyaratne, A. Balen, J. Barth, P. Belchetz.
Clinical manifestations and insulin resistance (IR) in polycystic ovary syndrome (PCOS) among South Asians and Caucasians: is there a difference?.
Clin Endocrinol, 57 (2002), pp. 343-350
[27.]
M.D. Kahsar-Miller, C. Nixon, L. Boots, R. Go, R. Azziz.
Prevalence of polycystic ovary syndrome (PCOS) in first-degree relatives of patients with PCOS.
Fertil Steril, 75 (2001), pp. 53-58
[28.]
W. Atiomo, E. El-Mahdi, P. Hardiman.
Familial associations in women with polycystic ovary syndrome.
Fertil Steril, 80 (2003), pp. 143-145
[29.]
D.A. Ehrmann, K. Kasza, R. Azziz, R. Legro, M. Ghazzi.
Effects of race and family history of type 2 diabetes on metabolic status of women with polycystic ovary syndrome.
J Clin Endocrinol Metab, 90 (2006), pp. 66-71
[30.]
S. Franks.
Adult polycystic ovary syndrome begins in childhood.
Best Pract Res Clin Endocrinol Metab, 16 (2002), pp. 263-272
[31.]
L. Ibáñez, C. Valls, N. Potau, M.V. Marcos, F. De Zegher.
Polycystic ovary syndrome after precocious pubarche: ontogeny of the low-birthweight effect.
Clin Endocrinol, 55 (2001), pp. 667-672
[32.]
D.J. Barker, P.M. Clark.
Fetal undernutrition and disease later in life.
Ren Reprod, 2 (1997), pp. 105-112
[33.]
J. Dimartino-Nardi.
Premature adrenarche: findings in prepubertal African-American and Caribbean-Hispanic girls.
Acta Paediatr Suppl, 88 (1999), pp. 67-72
[34.]
R.L. Rosenfield.
Hirsutism.
N Engl J Med, 353 (2005), pp. 2578-2588
[35.]
S.B. Reingold, R.L. Rosenfield.
The relationship of mild hirsutism or acne in women to androgens.
Arch Dermatol, 123 (1987), pp. 209-212
[36.]
D. Deplewski, R. Rosenfield.
Role of hormones in pilosebaceous unit development.
Endocr Rev, 21 (2000), pp. 363-392
[37.]
D.A. Ehrmann.
Medical progress: PCOS.
N Engl J Med, 352 (2005), pp. 1223-1236
[38.]
R. Azziz.
The evaluation and management of hirsutism.
Obstet Gynecol, 101 (2003), pp. 995-1007
[39.]
R.L. Rosenfield.
Pilosebaceous physiology in relation to hirsutism and acne.
J Clin Endocrinol Metab, 15 (1986), pp. 341-362
[40.]
I. Souter, L.A. Sánchez, M. Pérez, A.A. Bertolucci, R. Azziz.
The prevalence of androgen excess in women seeking treatment for minimal unwanted hair growth.
Am J Obstet Gyn, 191 (2004), pp. 1914-1920
[41.]
C. Slayden, W. Moran, L. Sams, R. Boots, R. Azziz.
Hyperandrogenemia in patients presenting with acne.
Fertil Steril, 75 (2001), pp. 889-892
[42.]
A.H. Carey, K.L. Chan, F. Short, D. White, R. Williamson, S. Franks.
Evidence for a single gene effect causing polycystic ovaries and male pattern baldness.
Clin Endocrinol (Oxf), 38 (1993), pp. 653-658
[43.]
W.F. Bergfeld.
Androgenetic alopecia: an autosomal dominant disorder.
Am J Med, 98 (1995), pp. S95-S98
[44.]
V.H. Price.
Treatment of hair loss.
N Engl J Med, 341 (1999), pp. 964-973
[45.]
A.H. Carey, D. Waterworth, K. Patel, D. White, J. Little, P. Novelli, et al.
Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17.
Hum Mol Genet, 3 (1994), pp. 1873-1876
[46.]
E. Cela, C. Robertson, K. Rush, E.I. Kousta, D. White, H. Wilson, et al.
Prevalence of polycystic ovaries in women with androgenic alopecia.
Eur J Endocr, 149 (2003), pp. 439-442
[47.]
E.A. Olsen.
The midline part: an important physical clue to the clinical diagnosis of androgenic alopecia in women.
J Am Acad Dermatol, 40 (1999), pp. 106-109
[48.]
M. Hunter, J. Sterrett.
PCOS: it's not just infertility.
Am Fam Phys, 62 (2000), pp. 1079-1088
[49.]
S. Kirchengast, J. Huber.
Body composition characteristics and body fat distribution in lean women with polycystic ovary syndrome.
Hum Reprod, 16 (2001), pp. 1255-1260
[50.]
A.H. Balen, G.S. Conway, G. Kaltsas, K. Techatrasak, P.J. Manning, C. West.
Polycystic ovary syndrome: the spectrum of the disorder in 1741 patients.
Hum Reprod, 10 (1995), pp. 2107-2111
[51.]
E. Talbott, D. Guzick, A. Clerici, S. Berga, K. Detre, K. Weimer, et al.
Coronary heart disease risk factors in women with PCOS.
Arterioscler Thromb Vasc Biol, 15 (1995), pp. 821-826
[52.]
T. Strowitzki, B. Halser, T. Demant.
Body fat distribution, insulin sensitivity, ovarian dysfunction and serum lipoproteins in patients with PCOS.
Gynecol Endocrinol, 16 (2002), pp. 45-51
[53.]
S. Kirchengast, D. Gruber, M. Sator.
The fat distribution index-a new possibility to quantify sex specific fat patterning in females.
Homo, 48 (1997), pp. 285-295
[54.]
K. Charnvises, S. Weerakiet, Y. Tingthanatikul, S. Wansumrith, S. Chanprasertyothin, A. Rojanasakul.
Acanthosis nigricans: clinical predictor of abnormal glucose tolerance in Asian women with polycystic ovary syndrome.
Gynecol Endocrinol, 21 (2005), pp. 161-164
[55.]
R. Azziz, L.A. Hincapie, E.S. Knochenhauer, D. Dewailly, L. Fox, L.R. Boots.
Screening for 21-hydroxylase deficient non-classic adrenal hyperplasia among hyperandrogenic women: a prospective study.
Fertil Steril, 72 (1999), pp. 915-925
[56.]
H.F. Escobar-Morreale, J.L. San Millán, R.R. Smith, J. Sancho, S.F. Witchel.
The presence of the 21-hydroxylase deficiency carrier status in hirsute women: phenotype-genotype correlations.
Fertil Steril, 72 (1999), pp. 629-638
[57.]
R. Azziz.
The time has come to simplify the evaluation of the hirsute patient.
Fertil Steril, 74 (2000), pp. 870-872
[58.]
T.A. Bachega, E.M. Brenlha, A.E. Billerbeck, J.A. Marcondes, G. Madureira, I.J. Arnhold, et al.
Variable ACTH-stimulated 17-hydroxyprogesterone values in 21-hydroxylase deficiency carriers are not related to the different CYP21 gene mutations.
J Clin Endocrinol Metab, 87 (2002), pp. 786-790
[59.]
F. Kelestimur, Y. Sahin.
Alternate pathway 17,20-lyase enzyme activity in the adrenals is enhanced in patients with polycystic ovary syndrome.
Fertil Steril, 71 (1999), pp. 1075-1078
[60.]
C.T. Erel, L.M. Senturk, E. Oral, U. Colgar, E. Ertungealp.
Adrenal androgenic response to 2-hour ACTH stimulation test in women with PCOS.
Gynecol Endocrinol, 12 (1998), pp. 223
[61.]
D. Glintborg, A.P. Hermann, K. Brusgaard, J. Hangaard, C. Hagen, M. Andersen.
Significantly higher adrenocorticotropin-stimulated cortisol and 17 hydroxyprogesterone levels in 337 consecutive, premenopausal, caucasian, hirsute patients compared with healthy controls.
J Clin Endocrinol Metab, 90 (2006), pp. 1347-1353
[62.]
C. Moran, R. Azziz.
The role of the adrenal cortex in polycystic ovary syndrome.
Obstet Gynecol Clin North Am, 28 (2001), pp. 63-75
[63.]
D. Glintborg, J. Henriksen, M. Andersen, C.I. Hagen, J. Hangaard, E. Rasmussen, et al.
Prevalence of endocrine diseases and abnormal glucose tolerance tests in 340 Caucasian premenopausal women with hirsutism as the referral diagnosis.
Fertil Steril, 82 (2004), pp. 1570-1579
[64.]
P.J. Rowe, F.H. Comhaire, T.B. Hargreave.
Female partner.
World Health Organization manual for the standardized investigation and diagnosis of the infertile couple, Cambridge University Press, (2000),
[65.]
J.S. Laven, B. Imani, M.J. Eijkemans, B.C. Fauser.
New approaches to PCOS and other forms of anovulation.
Obstet Gynecol Surv, 57 (2002), pp. 755-767
[66.]
B.C. Fauser, T.D. Pache, S.W. Lamberts, W.C. Hop, F.H. De Jong, K.D. Dahl.
Serum bioactive and immunoreactive LH and FSH levels in women with cycle abnormalities, with or without PCOD.
J Clin Endocrinol Metab, 73 (1991), pp. 811-817
[67.]
A.E. Taylor, B. McCourt, K. Martin, E.J. Anderson, J. Adams, D. Schoebfeld, et al.
Determinants of abnormal gonadotropin secretion in clinically defined women with PCOS.
J Clin Endocrinol Metab, 82 (1997), pp. 2248-2256
[68.]
J. Waldstreicher, N.F. Santoro, H.J.E. Hall, M. Filicori, W.F. Crowley.
Hyperfunction of the hypothalamic-pituitary axis in women with polycystic ovarian disease: indirect evidence of partial gonadotrophine desensitization.
J Clin Endocrinol Metab, 66 (1988), pp. 165-172
[69.]
M.H. Van Hooff, F.J. Voorhorst, M.B. Kaptein, R.A. Hirasing, C. Koppenaal, J. Schoemaker.
Endocrine features of polycystic ovary syndrome in a random population sample of 14-16 year old adolescents.
Hum Reprod, 14 (1999), pp. 2223-2229
[70.]
E. Carmina, F. Rosato, M. Maggiore, A.M. Gagliano.
Prolactin secretion: correlation with the steroid pattern.
Acta Endocrinol, 105 (1984), pp. 99-104
[71.]
H.A. Zacur, G.V. Foster.
Hyperprolactinemia and PCOS.
Semin Reprod Endocrinol, 10 (1992), pp. 236-245
[72.]
G.A. Kaltsas, M. Korbonits, A.M. Isidori, J.A. Webb, P.J. Trainer, J.P. Monson, et al.
How common are polycystic ovaries and the PCOS in women with Cushing's syndrome.
Clin Endocrinol (Oxf), 53 (2000), pp. 493-500
[73.]
G. Kaltsas, A. Isidori, B. Kola, R. Skelly, S. Chew, P. Jenkins, et al.
The value of the low dose dexamethasone test in the differential diagnosis of hyperandrogenism in women.
J Clin Endocrinol Metab, 88 (2003), pp. 2634-2643
[74.]
C.A. Matteoni, Z.M. Younossi, T. Gramlich, N. Bopari, Y.C. Liu, A.J. McCullough.
Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.
Gastroenterology, 116 (1999), pp. 1413-1419
[75.]
T. Setji, N. Holland, L. Sanders, N. Pereira, A. Diehl, A. Brown.
Nonalcoholic steatohepatitis and nonalcoholic fatty liver disease in young women with polycystic ovary syndrome.
J Clin Endocrinol Metab, 91 (2006), pp. 1741-1747
[76.]
J.M. Clark, F.L. Brancati, A.M. Diehl.
Nonalcoholic fatty liver disease.
Gastroenterology, 122 (2002), pp. 1649-1657
[77.]
J.B. Schwimmer, O. Khorram, V. Chiu, W.B. Schwimmer.
Abnormal aminotransferase activity in women with polycystic ovary syndrome.
[78.]
S.G. Sheth, F.D. Gordon, S. Chopra.
Nonalcoholic steatohepatitis.
Ann Intern Med, 126 (1997), pp. 137-145
[79.]
I.C. Gaemers, A.K. Groen.
New insights in the pathogenesis of non-alcoholic fatty liver disease.
Curr Opin Lipidol, 17 (2006), pp. 268-273
[80.]
A.N. Vgontzas, R. Legro, E. Bixler, A. Grayev, A. Kales, G. Chrousos.
Polycystic ovary syndrome is associated with obstructive sleep apnea and daytime sleepiness: role of insulin resistance.
J Clin Endocrinol Metab, 86 (2001), pp. 517-520
[81.]
A. Dunaif, D.P. White.
Increased prevalence of obstructive sleep apnea syndrome in obese women with polycystic ovary syndrome.
J Clin Endocrinol Metab, 86 (2001), pp. 1175-1180
[82.]
M. Gopal, S. Duntley, M. Uhles, H. Attarian.
The role of obesity in the increased prevalence of obstructive sleep apnea syndrome in patients with polycystic ovary syndrome.
Sleep Med, 3 (2002), pp. 401-404
[83.]
A.L. Hirschberg, S. Naessen, M. Stridsberg, B. Bystrom, J. Holtet.
Impaired cholecystokinin secretion and disturbed appetite regulation in women with polycystic ovary syndrome.
Gynecol Endocrinol, 19 (2004), pp. 79-87
[84.]
M.C. García-Rudaz, M.G. Ropelato, M.E. Escobar, J.D. Veldhuis, M. Barontini.
Amplified and orderly growth hormone secretion in lean adolescence with PCOS.
Eur J Endocrinol, 147 (2002), pp. 207-216
[85.]
F.V. Comim, P.M. Spritzer.
Increased growth hormone response to clonidine in nonobese normoinsulinemic patients with polycystic ovary syndrome.
Fertil Steril, 81 (2004), pp. 108-113
[86.]
M. Hara, K. Ichikawa, K. Minemura, H. Kobayashi, N. Suzuki, A. Sakurai, et al.
Acromegaly with polycystic ovaries, hyperandrogenism, hirsutism, insulin resistance and acanthosis nigricans: a case report.
Endocr J, 40 (1993), pp. 207-211
[87.]
R. Fox, P.G. Wardle, L. Clarke, M.G. Hull.
Acromegaloid bone changes in severe polycystic ovarian disease: an effect of hyperinsulinaemia? Case report.
Br J Obstet Gynaecol, 98 (1991), pp. 410-412
[88.]
J. Capeau, J. Magre, O. Lascols, M. Caron, V. Bereziat, C. Vigouroux, et al.
Diseases of adipose tissue: genetic and acquired lipodystrophies.
Biochem Soc Transplant, 33 (2005), pp. 1073-1077
[89.]
A.R. Borenstein, C.I. Copenhaver, J.A. Mortimer.
Early-life risk factors for Alzheimer disease.
Alzheimer Dis Assoc Disord, 20 (2006), pp. 63-72
[90.]
R.S. Legro, V.D. Castracane, R.P. Kaufmann.
Detecting insulin resistance in polycystic ovary syndrome: purposes and pitfalls.
Obstet Gynecol Surv, 59 (2004), pp. 141-154
Copyright © 2006. Sociedad Española de Endocrinología y Nutrición
Opciones de artículo
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos